Stockreport

Motif Bio announces iclaprim granted Orphan Drug Designation by US FDA for treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF NEW YORK, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (Nasdaq:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibi [Read more]